Reuters logo
BRIEF-Merck Q2 adjusted earnings per share $0.93
July 29, 2016 / 10:51 AM / a year ago

BRIEF-Merck Q2 adjusted earnings per share $0.93

July 29 (Reuters) - Merck Announces Second

* Q2 januvia/janumet sales $ 1,634 million versus $1,412 million in q1

* Second-Quarter pharmaceutical sales increased 2 percent to $8.7 billion

* Raised bottom end of its full-year 2016 non-gaap eps range

* Full-Year 2016 gaap eps range reflects impact of intangible asset impairment charges and higher restructuring costs incurred in q2

* Fy2016 earnings per share view $3.72, revenue view $39.49 billion -- Thomson Reuters I/B/E/S

* Merck & co inc qtrly keytruda total sales $314 million versus $110 million

* Fy 2016 revenue outlook includes an approximately 2 percent negative impact from foreign exchange at current exchange rates

* Quarter 2016 financial results

* Q2 non-gaap earnings per share $0.93

* Q2 gaap earnings per share $0.43

* Q2 sales $9.8 billion versus i/b/e/s view $9.78 billion

* Q2 earnings per share view $0.91 -- Thomson Reuters I/B/E/S

* Sees fy 2016 non-gaap earnings per share $3.67 to $3.77

* Sees fy 2016 gaap earnings per share $1.98 to $2.08

* Q2 remicade sales $339 million versus $455 million

* Merck has narrowed its full-year 2016 revenue range to be between $39.1 billion and $40.1 billion

* Lowered its full-year 2016 gaap eps range

* As of june 30, 2016, merck had approximately 68,000 employees worldwide Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below